What is the clinical evidence from this study?

Study design: Case-Control. Population: Carotid atherosclerotic plaque (n=20). Intervention: Plasma ceramide 22:0 vs. Healthy controls without carotid plaque. Primary outcome: Plasma level of ceramide 22:0 (μg/mL) (p=<0.05).

July 9, 2020Open Access

Elevated plasma levels of ceramide 22:0 were significantly associated with the presence of carotid atherosclerotic plaques compared to healthy controls (0.59 vs 0.41 μg/mL), independent of cholesterol levels.

Q: What are the key findings of this study?

Elevated plasma levels of ceramide 22:0 were significantly associated with the presence of carotid atherosclerotic plaques compared to healthy controls (0.59 vs 0.41 μg/mL), independent of cholesterol levels.

View Full Paper

Ask AI

Bookmark

Why the study?

Plasma lipidomics allows study of a wide spectrum of lipid species, but the roles of plasma lipid components in relation to atherosclerotic plaques needed exploration.

Comparison

Cases with carotid plaques vs controls without carotid plaque

Design

Case-control study

Key result

Elevated plasma levels of ceramide 22:0 were significantly associated with the presence of carotid atherosclerotic plaques compared to healthy controls (0.59 vs 0.41 μg/mL), independent of cholesterol levels.

Authors

GXGaoqiang Xie PMPhyo Kyaw Myint ZFZhong‐Ze Fang

Discussion

Member takes

Overview

Ceramide 22:0 may mark carotid atherosclerosis beyond cholesterol; hypothesis-generating and leaves open prospective validation for risk stratification.

Study Design

Type

Case-Control (n=20)

Randomization

Randomly selected from a community cohort

Multicenter

Structured PICO

Population

20 non-symptomatic adults (mean age 62.6 years, 45% female) from a Chinese community cohort, including 10 with multiple carotid plaques and 10 healthy controls.

Comparator

Healthy controls without any carotid plaque

Outcome

Difference in plasma lipid species (specifically ceramide 22:0) between cases with carotid plaque and healthy controlssurrogate

Main Result

Absolute Event Rate: 0.59% vs 0.41%

p-value: p=<0.05

Elevated plasma ceramide 22:0 is independently associated with carotid atherosclerotic plaques, suggesting it may be a novel biomarker and potential therapeutic target for atherosclerosis.

Limitations

Small sample size requiring future verification in larger cohorts
Cross-sectional design cannot establish a causal relationship
Potential degradation of lipid molecules during storage from 2012 to 2018
Use of whole plasma may dilute values compared to specific lipoprotein fractions
Did not match lipid profiles (total cholesterol, LDL-c) between cases and controls
Small sample size
Cross-sectional design cannot confirm causality
Use of whole plasma instead of lipoprotein fractions may dilute values
Did not match lipid profile between groups

Cite This Study

Xie et al. (2020) conducted a case-control in Carotid atherosclerotic plaque (n=20). Plasma ceramide 22:0 vs. Healthy controls without carotid plaque was evaluated on Plasma level of ceramide 22:0 (μg/mL) (p=<0.05). Elevated plasma levels of ceramide 22:0 were significantly associated with the presence of carotid atherosclerotic plaques compared to healthy controls (0.59 vs 0.41 μg/mL), independent of cholesterol levels.

synapsesocial.com/papers/6a730d4e613c305b15e0a956 https://doi.org/10.21203/rs.3.rs-38075/v1

View Full Paper

Ask AI

Bookmark

July 9, 2020Open Access

Elevated plasma levels of ceramide 22:0 were significantly associated with the presence of carotid atherosclerotic plaques compared to healthy controls (0.59 vs 0.41 μg/mL), independent of cholesterol levels.

View Full Paper

Ask AI

Bookmark

Why the study?

Plasma lipidomics allows study of a wide spectrum of lipid species, but the roles of plasma lipid components in relation to atherosclerotic plaques needed exploration.

Comparison

Cases with carotid plaques vs controls without carotid plaque

Design

Case-control study

Key result

Authors

GXGaoqiang Xie PMPhyo Kyaw Myint ZFZhong‐Ze Fang

Discussion

Member takes

Overview

Ceramide 22:0 may mark carotid atherosclerosis beyond cholesterol; hypothesis-generating and leaves open prospective validation for risk stratification.

Study Design

Type

Case-Control (n=20)

Randomization

Randomly selected from a community cohort

Multicenter

Structured PICO

Population

20 non-symptomatic adults (mean age 62.6 years, 45% female) from a Chinese community cohort, including 10 with multiple carotid plaques and 10 healthy controls.

Comparator

Healthy controls without any carotid plaque

Outcome

Difference in plasma lipid species (specifically ceramide 22:0) between cases with carotid plaque and healthy controlssurrogate

Main Result

Absolute Event Rate: 0.59% vs 0.41%

p-value: p=<0.05

Elevated plasma ceramide 22:0 is independently associated with carotid atherosclerotic plaques, suggesting it may be a novel biomarker and potential therapeutic target for atherosclerosis.

Limitations

Small sample size requiring future verification in larger cohorts
Cross-sectional design cannot establish a causal relationship
Potential degradation of lipid molecules during storage from 2012 to 2018
Use of whole plasma may dilute values compared to specific lipoprotein fractions
Did not match lipid profiles (total cholesterol, LDL-c) between cases and controls
Small sample size
Cross-sectional design cannot confirm causality
Use of whole plasma instead of lipoprotein fractions may dilute values
Did not match lipid profile between groups

Cite This Study

synapsesocial.com/papers/6a730d4e613c305b15e0a956 https://doi.org/10.21203/rs.3.rs-38075/v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark